on the behalf of GITMO Hepatitis B virus (HBV)-infected individuals are occasionally used as donors for bone marrow transplantation (BMT). We studied the rate of HBV infection and the clinical expression of the associated liver disease in patients receiving marrow from HBsAg' donors. We performed a retrospective survey in 14 BMT units in Italy in which all BMTs performed between 1984 and 1994 were reviewed and those involving HBsAg' donors were identified. Donors and recipients were analyzed for HBV markers and liver disease. A total of 24 of 2,586 patients (0.9%) had received an HBsAg' marrow. HBsAg became detectable in 2296 of pre-BMT HBsAg-patients, but only 5.5% became chronic HBsAg carriers. Antigenemia developed more frequently in anti-HBs-compared HE OCCURRENCE OF hepatic complications in bone marrow transplantation (BMT) recipients is a wellknown cause of transplant-related morbidity and mortality.' Besides venoocclusive disease and graft-versus-host disease of the liver, viral infections can cause hepatitis of variable clinical severity after marrow transplantation.
Hepatitis B virus (HBV)-infected individuals are occasionally used as donors for bone marrow transplantation (BMT).
We studied the rate of HBV infection and the clinical expression of the associated liver disease in patients receiving marrow from HBsAg' donors. We performed a retrospective survey in 14 BMT units in Italy in which all BMTs performed between 1984 and 1994 were reviewed and those involving HBsAg' donors were identified. Donors and recipients were analyzed for HBV markers and liver disease. A total of 24 of 2,586 patients (0.9%) had received an HBsAg' marrow. HBsAg became detectable in 2296 of pre-BMT HBsAg-patients, but only 5.5% became chronic HBsAg carriers. Antigenemia developed more frequently in anti-HBs-compared HE OCCURRENCE OF hepatic complications in bone marrow transplantation (BMT) recipients is a wellknown cause of transplant-related morbidity and mortality.' Besides venoocclusive disease and graft-versus-host disease of the liver, viral infections can cause hepatitis of variable clinical severity after marrow transplantation.
The profound impairment of the immune response in BMT patients can influence the clinical and serologic pattern of hepatitis B virus (HBV) infection, because the severity of the disease is partly due to the immune attack against viralinfected cells. Reactivation of HBV in asymptomatic hepatitis B surface antigen (HBsAg) carriers is recognized as a possible complication of immune suppression. Indeed, there are some reports of patients treated using high-dose chemotherapy or BMT who died with fulminant hepatitis due to reactivation of latent HBV infection after immune reconstituti~n.'.~ However, these observations have not been confirmed in three large series of BMT patients with active HBV infection either before or after tran~plantation.~"
In some European countries, including Italy, the prevalence of HBV infection in the healthy population is not negligible (1% to 3%). This prevalence is also reflected in a higher proportion of BMT patients with HBsAg positivity.' The chance of having only a single related BMT donor who is infected with HBV is not an exceptional event. It is therefore important to ascertain the risk of infusion of HBsAg+ marrow. There are few published data on the matter, which often report contradicting c~n c l u s i o n s .~~~ This lack of information leads to a wide variability in BMT policy in the presence of HBsAg' donors, as has emerged in a recent survey.' We thought it was important to evaluate this problem by studying retrospectively patients who had received an HBsAg' marrow who were being treated in Italian centers belonging to the Gruppo Italiano Trapianto di Midollo (GITMO). The hepatologic events and the pattern of HBV serologic markers occurring after BMT were evaluated in relation to the presence of HBeAg and of anti-HBe in the donor.
MATERIALS AND METHODS
A questionnaire was sent to all Italian Bone Marrow Transplantation (GITMO) member centers in September 1994 to collect data on all BMT cases receiving transplants from an HBsAg+ donor in the last decade. In these centers, all patients and donors had been regularly screened for HBsAg. The data form required information on: (1) the donor: hepatitis B e antigen (HBeAgYantibody (antiHBe) status, the presence of liver disease, donor age, and donor gender; and (2) the patient: pretransplant characteristics (age, gender, hematologic diagnosis, type of conditioning regimen, graft-versushost disease [GVHD] prophylaxis, HBV serology, and the presence of liver disease) and posttransplant clinical and serologic events. A total of 14 of 28 GITMO centers responded, with 8 reporting no cases and 6 providing a total of 24 patients who had received marrow from an HBsAg+ donor. Each marrow recipient had given informed consent to receive marrow from a known HBsAg-seropositive individual. Table 1 summarizes the patient characteristics at transplantation and the type of BMT protocols used.
HBV markers and assessment of liver disease. Before transplantation, marrow transplant recipients and donors were screened for HBsAg, hepatitis B surface antibody (anti-HBs), hepatitis B core antibody (anti-HBc), HBeAg, and anti-HBe using commercial radioimmunoassays. Patients' sera were serially tested for HBV markers after transplantation for at least 180 days or up to the time of death if death occurred before day +l80 (day 0 is the day of marrow infusion). Patients who developed HBsAg positivity were tested for the persistence of antigenemia up to the time of last follow-UP.
All of the 24 patients underwent clinical and biochemical assess- 
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ALT Blood components administered to the patients were obtained from HBsAg-volunteer donors.
The statistical analysis was performed using Fisher's exact test.
RESULTS
A total of 24 of 2,586 patients received a marrow infusion from an HBsAg+ donor (0.9%).
Donors' characteristics. The 24 HBsAg+ donors had a median age of 30 years (range, 12 to 51 years). There was 15 male patients and 9 female patients. Transaminase levels were normal in 22 and slightly elevated (15 times the upper normal value) in the remaining 2 individuals.
Patients' characteristics. Characteristics of marrow recipients and details of the conditioning regimen, GVHD prophylaxis, and the number of patients receiving specific Ig prophylaxis are given in Table 1 .
Overall, posttransplant observation lasted for a median of 33 1 days (range, 37 to 3,650 days). The follow-up restricted to the alive patients ranged from 180 to 3,650 days (median, 700 days). Table 2 summarizes the HBV profile in the 24 donorhecipient pairs studied, whereas Table 3 summarizes the clinical characteristics and type of posttransplant liver disease observed in the 24 patients.
Transmission of HBV infection. Six patients ( Table 2) were HBsAg+ before transplant and remained so for the 3237 entire follow-up period. Four of 18 HBsAg-recipients (22%) developed antigenemia after marrow infusion. Of these, only 1 patient became an HBsAg carrier, whereas the other 3 patients lost the antigen during follow-up, with seroconversion to anti-HBs occurring in 2 ( Table 2) . Ten patients were anti-HBs' at transplantation (Table 2) ; antigenemia appeared in 1 patient, compared with 3 of 8 of the anti-HBs-cases ( P not significant). Nine patients (including 1 who was always positive for HBsAg) received anti-HBs prophylaxis. Posttransplantation HBsAg positivity was independent of the administration of specific Ig (2 of 8 treated v 2 of 10 untreated;
When the presence of pre-BMT anti-HBs or its appearence after transplant due to passive prophylaxis were combined, excluding patients with HBsAg positivity before BMT, HBsAg positivity developed in 1 of 11 anti-HBs' cases versus 3 of 7 anti-HBs-cases.
Liver disease after BMT. Seven patients (29%) experienced acute hepatitis after BMT, 8 (33%) experienced chronic hepatitis, and 4 (17%) never developed liver complications (Table 3) . Post-BMT liver failure occurred in 5 of 24 cases (21%), 1 due to venoocclusive disease and 4 to subacute hepatitis. This figure is extremely high when compared with that observed in a large series of unselected Italian patients undergoing BMT, in which 71 of 1,908 patients (3.7%) developed liver failure,' as well as when compared with that observed when BMT is performed in HBsAg' patients Abbreviations: AML, acute myeloid leukemia; CML, chronic myeloid leukemia; ALL, acute lymphoblastic leukemia; SAA, severe aplastic anemia; Tha1.M.. thalassemia major; CR. complete remission; cp. chronic phase; ac, accelerated phase; rel, relapse; CV, cyclophosphamide; BU, busulphan; TBI, total body irradiation; LF, liver failure; H, hepatitis.
The occurrence and type of liver disease were evaluated in 23 of 24 donorlpatient pairs with available data on HBeAg/anti-HBe donor status. Death because of liver failure occurred in 0 of 5 recipients of HBeAg+ marrow and in 5 of 18 cases receiving anti-HBe+ marrow (28%; P = not significant). The seventy of liver disease, analyzed by comparing transaminase peaks, showed no significant difference between the two groups, although somewhat higher peak values were observed in patients receiving transplants from an anti-HBe+ donor ( Table 4) .
We then studied the course of liver disease after BMT according to the pretransplant HBsAg/anti-HBs status in 23 patients with available data. The ALT peak levels were lower in patients positive for anti-HBs before transplantation when compared with HBsAg+ or HBsAg/anti-HB-cases, but there was a wide range of values in the three groups and differences were not statistically significant ( Table 4) . Although the proportion of patients developing acute or chronic hepatitis after BMT was comparable in anti-HBs+ or antiHBs-cases, none of the 10 patients anti-HBs+ before transplant died of liver failure (Fig 1) and 2 of 10 had no liver disease. The opposite was seen in the anti-HBs-group, in which liver failure occurred in 4 of 13 and only 1 patient showed no liver problems after transplantation (Fig 1) . These differences did not reach statistical significance but may suggest a trend for the presence of anti-HBs before transplant to be protective against occurrence of fatal liver disease. To ascertain whether passive immunization against HBV was protective as well, we compared the severity of liver disease in patients who were negative for anti-HBs before BMT and had been treated or not with specific Ig before transplant. Liver failure occurred in 1 of 5 treated versus 3 of 8 untreated patients ( P = not significant).
DISCUSSION
This study presents the largest series of patients receiving a BMT from an HBsAg+ donor reported to date. It represents a unique example of the simultaneous in vivo infusion of HBV-infected blood and immunocompetent cells; this procedure is ethically justified because it offers the best therapeutic 
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Anti-HBschoice for such patients. It has been suggested that post-BMT liver disease may be more severe in this setting and, indeed, fatal liver failure was overall more frequent when compared with frequencies observed with HBsAg-donors, which range in Europe from 0% to 12% (in Italy the frequency is 3.7%).n It was of interest to note that severe liver failure was not more frequent in the recipients of BMT from
HBeAg' donors, in whom viremia levels are known to be higher, but was instead seen mainly in patients with an antiHBe' donor. In these latter cases, peak ALT levels were higher than those observed in recipients of HBeAg+ marrow even in the group not developing liver failure, again suggesting a more cytopathic effect of HBV acquired from antiHBe' donors. However, the difference was not statistically significant. It should be also considered that other causes of liver disfunction or failure not examined in the study might also have been involved. Indeed, our analysis was focused only on HBV infection; donor positivity for other potential pathogens, such as hepatitis C virus, delta virus, or cytomegalovirus, was not assessed. The rate of HBsAg positivity observed in our patients was lower than expected, taking into consideration that all of the patients were receiving HBsAg' marrow at the time of profound immunodeficiency. The origin of the immunocompetent transplanted cells from an HBV carrier known to be tolerant against the virus should have further favored such an outcome. However, only 4 of 18 HBsAg-recipients (22%) developed antigenemia after transplantation and only 1 of them remained persistently infected by HBV. On the other hand, all HBsAg' recipients remained caniers after transplantation. The low rate of HBV chronicity observed in this study is in agreement with the results of a previous study in which we noticed that none of the 21 patients who developed HBsAg positivity after BMT became an HBsAg carrier. However, it should be stressed that anti-HBs positivity, either present before transplantation or detected after passive prophylaxis with anti-HBsIg, may have influenced our results by masking HBsAg positivity. Indeed, HBsAg became detectable after BMT in 42.8% of pre-BMT HBsAg-individuals if anti-HBs was not present either before or after BMT, compared with only 9% of similar patients with antiHBs. However, these figures remain far below that reported in patients undergoing BMT from hepatitis C virus-infected donors.'' It is also of interest that patients presenting at transplantation with anti-HBs seropositivity developed less severe liver disease after BMT compared with anti-HBs-patients, although this difference did not reach statistical significance, mainly due to the small number of patients. The results from these groups, which obviously need to be confirmed on a prospective basis, would suggest that anti-HBs passive prophylaxis could be helpful in anti-HBs-BMT recipients to protect from severe liver disease when an HBsAg' donor must be used.
